Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
WEBINAR | Join top cancer researchers to explore advances transforming early discovery, from new targets and models to the therapies of tomorrow

List view / Grid view

Hit-to-Lead

 

news

Midatech Pharma awarded EU grant funding to support training and research into glycan based multivalent immunotherapeutics

17 December 2014 | By Midatech Pharma

Midatech Pharma, a nanomedicine company developing and commercialising multiple therapeutic products to enhance the delivery of medicines in major diseases with high unmet medical needs, is pleased to announce that a consortium of academic and industry groups including Midatech has been awarded a €3.8 million European Union grant...

news

New targeted drugs could treat drug-resistant skin cancer

15 December 2014 | By The Institute of Cancer Research, London, and Cancer Research UK Manchester Institute

A brand new family of cancer drugs designed to block several key cancer-causing proteins at once could potentially treat incurable skin cancers, a major new study reports...

news

International College of Neuropsychopharmacology (CINP) calls on governments to reverse ‘disturbing’ trend of lack of new drugs for the 10% of the global population affected by brain diseases

2 December 2014 | By The International College of Neuropsychopharmacology

The International College of Neuropsychopharmacology (CINP) has published a paper in Nature Reviews Drug Discovery on how global governments must act to address the dearth of new drugs for central nervous system (CNS) diseases...

news

MRC Technology and Yabao Pharmaceuticals announce exclusive partnership in China to develop novel therapeutics for Parkinson’s disease

24 November 2014 | By MRC Technology / Yabao Pharmaceuticals

MRC Technology and Yabao Pharmaceutical Co, Inc. today announced an exclusive license agreement to discover, develop and commercialise innovative compounds targeting a specific kinase involved in neurodegeneration, with the aim of developing novel therapeutics for the treatment of Parkinson’s disease...